Funding for this research was provided by:
National Cancer Institute (1U24CA199374-01, R01CA202752-01A1, R21CA179327-01, R21CA195152-01)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK098503-02)
U.S. Department of Defense (PC120857, LC130463, Prostate Cancer Idea Development Award)
School of Medicine, Case Western Reserve University (Comprehensive Cancer Center Pilot Grant)
Cleveland Clinic (VelaSano)
Case Western Reserve University Department of Biomedical Engineering (Wallace Coulter Foundation)
Received: 27 October 2017
Accepted: 26 April 2018
First Online: 30 May 2018
Ethics approval and consent to participate
: The study was HIPAA compliant and was approved by the Institutional Review Board at the University Hospitals Case Medical Center. The informed consent was waived by the institutional review board for this retrospective study.
: Dr. Madabhushi is an equity holder in Elucid Bioimaging and in Inspirata Inc. He is also a scientific advisory consultant for Inspirata Inc. In addition, he currently serves as a scientific advisory board member for Inspirata Inc. and for Astrazeneca. He also has sponsored research agreements with Philips and Inspirata Inc. His technology has been licensed to Elucid Bioimaging and Inspirata Inc. He is also involved in a NIH U24 grant with PathCore Inc. and a R01 with Inspirata Inc. Drs John Tomaszewski. Michael Feldman and Shridar Ganesan are members of the scientific advisory board of Inspirata, Inc. a digital pathology start-up company, and receives board fees and stock options. The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.